Recent 8-K filings for OMER

• August 13, 2026, 4:05 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Omeros appoints Joseph Schocken to board, expands to nine directors

  Board increased to nine directors; Joseph Schocken appointed effective Aug 12, 2026.

• August 12, 2026, 4:09 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24

  YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.

• July 20, 2026, 5:05 PM ET debt materiality 0.65 neutral item 8.01

  Omeros repurchases $14.5M of convertible notes; total $30.5M retired, $40.3M remains

  Repurchased $14.5M principal of 9.50% Convertible Senior Notes due 2029 for ~$29.0M total (incl. accrued interest).

• July 6, 2026, 8:30 AM ET debt materiality 0.55 neutral item 8.01

  Omeros to repurchase additional $14.5M of 9.50% Convertible Notes due 2029

  Previously disclosed repurchase of $16.0M principal for ~$31.3M expected to close July 6, 2026.

• June 25, 2026, 6:02 AM ET other materiality 0.10 neutral item 5.07

  Omeros shareholders elect three Class II directors, approve compensation and incentive plan

  Thomas J. Cable, Peter A. Demopulos, and Diana T. Perkinson elected as Class II directors to 2029 term; votes ranged from 20.8M to 25.3M for.

• June 18, 2026, 7:52 AM ET debt materiality 0.55 neutral item 8.01

  Omeros to repurchase up to $16M principal of 9.50% Convertible Notes for ~$34M

  Repurchase of up to $16.0M aggregate principal amount of 9.50% Convertible Senior Notes due 2029.

• May 13, 2026, 4:06 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net income $56.1M on $73.1M non-cash gain; YARTEMLEA net sales $9.9M

  GAAP net income $56.1M ($0.78/share) vs. net loss $33.5M ($0.58) in Q1 2025; includes $73.1M non-cash gain on embedded derivatives.

• March 31, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed

  Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).

• January 7, 2026, 6:59 PM ET other material materiality 0.50 neutral item 2.02

  Omeros reports preliminary cash and short-term investments of $171.5M at year-end 2025

  Preliminary unaudited cash and short-term investments of $171.5M as of Dec 31, 2025.

• December 29, 2025, 6:59 PM ET other material materiality 0.90 positive item 9.01

  FDA approves Omeros' YARTEMLEA as first therapy for TA-TMA; launch set for Jan 2026

  YARTEMLEA (narsoplimab-wuug) approved for adults and children ≥2 years with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

• December 1, 2025, 6:59 PM ET M&A materiality 0.95 positive item 1.02item 2.01item 9.01 ◈ M&A Transactions◈ Material Agreements

  Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback

  Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.

• November 13, 2025, 6:59 PM ET other material materiality 0.90 positive item 2.02item 9.01

  Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B

  Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).

• October 15, 2025, 7:59 PM ET M&A materiality 0.95 positive item 1.01item 8.01item 9.01

  Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B

  Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.

• August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M

  Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.

• July 25, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025

  Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.

• July 2, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Omeros shareholders elect directors, approve say-on-pay, ratify Ernst & Young

  Arnold C. Hanish elected Class I director with 16,033,755 for, 1,245,397 against.

• May 16, 2025, 7:59 PM ET other material materiality 0.05 neutral item 9.01

  Omeros files 8-K/A to correct omitted table in Second Supplemental Indenture

  Amendment filed solely to replace Exhibit 4.2 with corrected version including missing table.

• May 15, 2025, 7:59 PM ET earnings materiality 0.85 neutral item 1.01item 2.02item 2.03item 3.02item 8.01item 9.01 ◈ Debt Financings

  Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%

  Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.

• May 6, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025

  FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.

• March 31, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025

  Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.

• February 20, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025

  Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.

• January 16, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter

  Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.

• December 19, 2024, 6:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival

  Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting

  Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan

  Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.

• June 12, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 5.07 ◈ executive_change ×2

  Omeros CFO Jacobsen retiring June 30; Borges appointed successor

  Michael A. Jacobsen retires as VP Finance, CAO & Treasurer effective June 30, 2024; stays as part-time advisor at $5k/month.

• June 3, 2024, 7:59 PM ET debt materiality 0.85 positive item 1.01item 2.03item 7.01item 8.01item 9.01

  Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt

  New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal

  Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.

• April 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale

  Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.

• February 7, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 2.03

  Omeros amends royalty deal with DRI, receives $115M for expanded OMIDRIA royalty sale

  Omeros received $115M cash from DRI Healthcare Acquisitions LP for an expanded interest in OMIDRIA royalties.

• November 9, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024

  Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.

• October 16, 2023, 7:59 PM ET other material materiality 0.85 negative item 8.01item 9.01

  Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued

  Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).

• August 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set

  Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.

• June 28, 2023, 7:59 PM ET other material materiality 0.35 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×5

  Omeros shareholders approve 5M share increase in incentive plan, elect directors

  Thomas J. Cable, Peter A. Demopulos, M.D., and Diana T. Perkinson, M.D. elected as Class II directors with majority votes.

• May 16, 2023, 7:59 PM ET leadership materiality 0.20 neutral item 5.02 ◈ executive_change

  Omeros appoints Dr. Diana T. Perkinson to board of directors

  Board size increased to nine; Dr. Perkinson appointed effective May 12, 2023.

• May 9, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH

  Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.

• March 13, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales

  Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.

• February 6, 2023, 6:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M

  Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.

• November 9, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Omeros reports Q3 2022 net loss $17.5M; FDA denies narsoplimab appeal, provides resubmission path

  Net loss $17.5M ($0.28/share) vs $22.7M loss in 3Q21; cash and equivalents $221M at Sept 30.

• October 6, 2022, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03

  Omeros sells portion of OMIDRIA royalties for $125M; total capped payments of $188.4M through 2030

  Received $125M upfront from DRI Healthcare for partial sale of OMIDRIA royalties.

• August 9, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August

  Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.

• June 24, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Omeros holds 2022 annual meeting; shareholders re-elect two directors and ratify auditor

  Arnold C. Hanish re-elected as Class I director with 17.5M for, 8.6M against, 0.9M abstain.

• May 10, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution

  Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.

• March 1, 2022, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share

  Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.

• December 30, 2021, 6:59 PM ET M&A materiality 0.90 positive item 2.01item 8.01item 9.01

  Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties

  Received ~$126M cash at closing; retains accounts receivable.

• December 2, 2021, 6:59 PM ET M&A materiality 0.90 positive item 1.01item 8.01item 9.01

  Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties

  Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.

• November 9, 2021, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab

  OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.

• October 18, 2021, 7:59 PM ET regulatory materiality 0.90 negative item 5.02item 7.01item 8.01item 9.01 ◈ executive_change

  Omeros receives FDA Complete Response Letter for narsoplimab BLA; director Ray Aspiri retires

  Ray Aspiri retired from Omeros board effective Oct 14, 2021, with no disagreement with the company.

• October 1, 2021, 7:59 PM ET regulatory materiality 0.90 negative item 8.01item 9.01

  Omeros receives FDA deficiency notice for narsoplimab BLA; PDUFA date expected to be missed

  FDA identified deficiencies in narsoplimab BLA for HSCT-TMA, precluding labeling/post-marketing discussions.

• August 9, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17

  OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.75 · Most common event earnings

16 positive 6 negative 28 neutral

source · OMER on sec.gov